Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE

PFIZER INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : Who, when and how? A look at the UK's vaccination rollout

12/02/2020 | 11:18am EST

LONDON (AP) — British regulators have become the first to authorize the COVID-19 vaccine developed by American drugmaker Pfizer and Germany’s BioNTech for emergency use. Because trials of the vaccine have shown it has 95% efficacy, there is acute interest in how the U.K. plans to implement what is its biggest immunization program in decades. Here's a look at what is known about Britain's vaccination plan:

HOW MUCH OF THE VACCINE DOES THE U.K. HAVE?

Not enough. The U.K. has put in orders for 40 million doses, which can inoculate 20 million people, since each person gets two doses 21 days apart. Other vaccines will be needed for all the 53 million or so people eligible for shots; the U.K. only plans to immunize the population over age 16.

WHEN WILL THE ROLLOUT BEGIN?

The plan is to start a phased rollout of the Pfizer/BioNTech vaccine early next week across the U.K., including from 50 “hospital hubs” in England. Around 800,000 doses are slated to arrive from Belgium in the coming days. The aim is for the bulk of the first deliveries to be used on the most “at-risk" groups — nursing home residents and their caregivers, as well as people over age 80. The National Health Service will take the lead in the rollout of the vaccine, which eventually will expand to pharmacies and specially built vaccination centers.

HOW WILL THE ROLLOUT WORK?

It won't be straightforward. Because the vaccine must be stored and transported at about minus 70 degrees Celsius (minus 94 degrees Fahrenheit), there are clear logistical issues. Fortunately, the vaccine is stable at normal refrigerator temperatures, between 2 and 8 degrees Celsius (35.6 to 46.4 F), for a few days, meaning that it can be stored locally ahead of being administered.

Another complication arises from doses coming in packs of 975 that cannot be divided at the moment, making it impossible to deliver vaccines to individual care homes. NHSEngland Chief Executive Simon Stevens said he hoped authorities will approve a safe way of splitting up the dose packs so the jabs can get to care homes this month in the “first tranche of priorities.”

HOW LONG WILL THE VACCINATION EFFORT TAKE?

Months. The British government aims to have the most vulnerable sections of the population vaccinated by April. Because the U.K. won't have enough of the Pfizer/BioNTech vaccine, it will need other ones. Two candidates are currently being assessed. The one from American biotechnology company Moderna had similar efficacy rates as Pfizer/BioNTech's. Another vaccine from the University of Oxford and British pharmaceutical company AstraZeneca had a lower efficacy rate but is the cheapest. The U.K. has bought 100 million doses of the Oxford vaccine. If approved it is widely expected to be used on people who are not in the vulnerable groups listed in the first phase of Britain’s immunization program.

WILL THE U.K. MAKE VACCINES COMPULSORY?

No. Taking the vaccine will be voluntary, but the government and public health bodies are strongly urging everyone to get it. There will be no specific precautions required for anyone who has already had COVID-19, and there will be no mandatory testing for the virus.

WHO WILL BE VACCINATED FIRST?

The most vulnerable. The independent Joint Committee on Vaccination and Immunization, which advises the British government, said those most at risk of dying from COVID-19 should be top of the priority list. So elderly people in nursing homes and their caregivers will be the first priority, followed by people aged over 80 and front-line health workers.

AND THEN WHO IS NEXT?

All residents 75 and older should be vaccinated next, according to the JCVI, followed by those age 70 and over and people deemed to be clinically “extremely vulnerable.” During the first phase of the immunization program, Britain has created nine separate groups down to those age 50 and above. Overall, it hopes that between 90-99% of people most at risk of dying from COVID 19 will have been immunized during the first phase.

IS THE VACCINATION PLAN SET IN STONE?

No. The JCVI acknowledged that the scale of the vaccination program is unprecedented and that flexibility will be required, not least in how to transport the vaccine to care homes.

WHAT ABOUT ACCESS FOR OTHER HARD-HIT GROUPS?

As the rollout gathers steam, the JCVI is also advising local NHS providers, public health teams and community leaders to keep an eye out for any potential health inequalities linked to ethnicity, deprivation or access to health care. Studies have shown a disproportionate number of people from poorer households and from ethnic minorities have died during Britain's coronavirus outbreak. The U.K. has seen nearly 60,000 virus-related deaths, Europe's highest death toll in the pandemic.

HOW LONG BEFORE IMMUNITY KICKS IN?

Within a month. Data from the vaccine trials, which involved more than 40,000 people around the world, show a similar immune response, irrespective of age, race or country the volunteers lived in. Partial immunity does occur after the first dose, but British regulators expect people to become immune about seven days after the second dose. It is not yet exactly clear how long that immunity lasts.

WHAT'S THE LONG-TERM PLAN?

There are a number of answers that will only emerge through the test of time, such as its impact on transmission rates. It's also not clear how long immunity will last and whether people will need an annual dose of the vaccine, as with the flu vaccine. The U.K. will set up a monitoring program, whereby people will be asked to help build up knowledge. First up will be side-effects. They are expected to be modest, lasting a day or so and equivalent to those after other vaccines.

WHAT ABOUT ANTI-VAXXERS?

Britain'sMedicines and Healthcare Products Regulatory Agency, which authorized the Pfizer-BioNTech vaccine, insists no corners were cut in the process and that the experience of the rollout will show that the vaccine is safe and effective. The government has also indicated it will seek to stem misinformation and is thought to be actively recruiting well-respected people to front a national immunization ad campaign.

Follow AP coverage of the virus outbreak at https://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak

Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 2.86% 108.44 Delayed Quote.33.02%
PFIZER INC. 0.19% 36.55 Delayed Quote.-0.71%
All news about PFIZER INC.
03:26pTHE LATEST : Chicago opens restaurants, some bars with limits
AQ
01:09pUK vaccine roll-out speeds up but doctors want quicker second dose
RE
12:50pAstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
DJ
11:41aPFIZER : UK doctors seek review of 12-week gap between vaccine doses
AQ
11:38aItaly PM says vaccine supply delays are serious contract violations
RE
11:31aItaly pm conte says delays in vaccine supplies from pfizer, astrazeneca unacc..
RE
06:07aTHE LATEST : UK doctors want review of Pfizer shot timetable
AQ
01/22PFIZER : Provinces doing 'extraordinary' job to avoid wasting doses of COVID-19 ..
AQ
01/22Pfizer to supply 40M COVID-19 shots for poor countries
AQ
01/22ASTRAZENECA : to supply 31 mln COVID-19 shots to EU in first quarter, a 60% cut ..
RE
More news
Financials (USD)
Sales 2020 48 180 M - -
Net income 2020 19 782 M - -
Net Debt 2020 43 510 M - -
P/E ratio 2020 11,8x
Yield 2020 3,98%
Capitalization 203 B 203 B -
EV / Sales 2020 5,12x
EV / Sales 2021 4,43x
Nbr of Employees 88 300
Free-Float 59,1%
Chart PFIZER INC.
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 41,94 $
Last Close Price 36,55 $
Spread / Highest target 45,0%
Spread / Average Target 14,8%
Spread / Lowest Target -1,50%
EPS Revisions
Managers and Directors
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-0.71%203 159
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
ABBVIE INC.3.46%195 720